1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Tepotinib in patientswith NSCLC harbouringMET exon 14 skipping:Japanese subsetanalysis from thePhase II VISION study Hiroshi SakaiMasahiro MoriseTerufumi Kato2021 год

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: MET exon 14 skipping is an oncogenic driver occurring in 3-4% of non-small cell lung cancer (NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipping NSCLC. Here, we present data from Japanese patients in the Phase II VISION study, evaluating the efficacy and safety of tepotinib.
Год издания: 2021
Авторы: Hiroshi Sakai, Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Tomohiro Sakamoto, Toru Kumagai, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroshi Tanaka, Kenichi Chikamori, Naofumi Shinagawa, Hiroaki Takeoka, Rolf Bruns, Josef Straub, Karl Maria Schumacher, Paul K. Paik
Издательство: Oxford University Press
Источник: Japanese Journal of Clinical Oncology
Ключевые слова: Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies
Другие ссылки: Japanese Journal of Clinical Oncology (PDF)
Japanese Journal of Clinical Oncology (HTML)
PubMed Central (HTML)
PubMed (HTML)